1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Porton Pharma Solutions Ltd.
  6. Summary
    300363   CNE100001S57

PORTON PHARMA SOLUTIONS LTD.

(300363)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-08-17
62.80 CNY   -0.60%
08/04Porton Pharma Solutions Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.
CI
08/04Porton Pharma Solutions Ltd. authorizes a Buyback Plan.
CI
06/13PORTON PHARMA SOLUTIONS LTD.(SZSE : 300363) added to Shenzhen Stock Exchange Component A Share Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
08/15/2022 08/16/2022 08/17/2022 08/18/2022 08/19/2022 Date
63.4 63.68 63.18 62.8 61.74 Last
6370416 5249161 6976634 6553608 5531005 Volume
-2.37% +0.44% -0.79% -0.60% -1.69% Change
Estimated financial data (e)
Sales 2022 7 695 M 1 134 M 1 134 M
Net income 2022 1 371 M 202 M 202 M
Net Debt 2022 - - -
P/E ratio 2022 24,5x
Yield 2022 0,78%
Sales 2023 8 573 M 1 263 M 1 263 M
Net income 2023 1 552 M 229 M 229 M
Net Debt 2023 - - -
P/E ratio 2023 21,6x
Yield 2023 0,91%
Capitalization 33 597 M 4 951 M 4 951 M
Capi. / Sales 2022 4,37x
Capi. / Sales 2023 3,92x
Nbr of Employees 4 158
Free-Float 51,9%
More Financials
Company
Porton Pharma Solutions Ltd., formerly Porton Fine Chemicals Ltd., is a China-based company principally engaged in the provision of customized pharmaceutical research and production services. The Company is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer,... 
Sector
Pharmaceuticals
Calendar
08/20Earnings Release
More about the company
Ratings of Porton Pharma Solutions Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about PORTON PHARMA SOLUTIONS LTD.
08/04Porton Pharma Solutions Ltd. announces an Equity Buyback for CNY 100 million worth of i..
CI
08/04Porton Pharma Solutions Ltd. authorizes a Buyback Plan.
CI
06/13PORTON PHARMA SOLUTIONS LTD.(SZSE : 300363) added to Shenzhen Stock Exchange Component A S..
CI
06/13PORTON PHARMA SOLUTIONS LTD.(SZSE : 300363) added to Shenzhen Stock Exchange Component Ind..
CI
04/28Porton Pharma Solutions Ltd. Reports Earnings Results for the First Quarter Ended March..
CI
04/21Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 202..
CI
04/19Porton Pharma Solutions Ltd. Announces Board Appointments
CI
04/19Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021
CI
03/28Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021
CI
02/28Porton Pharma Solutions Ltd. Reports Earnings Results for the Full Year Ended December ..
CI
02/28Jiangxi Porton Pharmaceutical Co., Ltd. announced that it expects to receive CNY 334.80..
CI
02/14Three Chinese Drugmakers Deny Receiving Orders From Pfizer
MT
02/14Porton Pharma Bags $681 Million Purchase Order From Pfizer
MT
02/13Porton pharma set to open up 20% after co says it receives order…
RE
2021Porton Pharma Solutions Ltd. Reports Earnings Results for the Nine Months Ended Septemb..
CI
More news
News in other languages on PORTON PHARMA SOLUTIONS LTD.
08/04PORTON PHARMA SOLUTIONS LTD. (SZSE : 300363) annonce un rachat d'actions pour une valeur d..
08/04Porton Pharma Solutions Ltd. autorise un plan de rachat.
04/28Porton Pharma Solutions Ltd. annonce ses résultats pour le premier trimestre se termina..
04/21Porton Pharma Solutions Ltd. annonce un dividende final pour 2021, payable le 28 avril ..
04/19Porton Pharma Solutions Ltd. annonce des nominations au conseil d'administration
More news
Chart PORTON PHARMA SOLUTIONS LTD.
Duration : Period :
Porton Pharma Solutions Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PORTON PHARMA SOLUTIONS LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 61,74 CNY
Average target price 118,18 CNY
Spread / Average Target 91,4%
EPS Revisions
Managers and Directors
Nian Feng Ju Chairman & General Manager
Yong Qing Guo Independent Director
Pei Min Zheng Independent Director
Ji Hong Lai Independent Director
Rong Tao Vice Chairman, Secretary & Deputy General Manager
Sector and Competitors
1st jan.Capi. (M$)
PORTON PHARMA SOLUTIONS LTD.-29.79%5 036
JOHNSON & JOHNSON-2.51%438 468
ELI LILLY AND COMPANY14.66%300 939
ROCHE HOLDING AG-15.60%275 743
PFIZER, INC.-17.73%272 648
ABBVIE INC.4.35%249 814